1ST CANADIAN SYMPOSIUM ON MANAGING TOXICITIES OF EMERGING CANCER THERAPIES (CAN-TOX)
HYBRID EVENT
Join us at CAN-TOX, a premier hybrid event dedicated to advancing the management of toxicities associated with cutting-edge cancer therapies, including checkpoint inhibitors, cell therapies (CAR-T and BiTEs), antibody-drug conjugates (ADCs), and novel tyrosine kinase inhibitors (TKIs).
This dynamic symposium unites leading experts across disciplines to explore:
- The mechanisms driving therapy-related toxicities
- Cutting-edge diagnostic tools
- Evidence-based, multidisciplinary management strategies
- The latest breakthroughs in toxicity research
Don’t miss this exceptional opportunity to engage with thought leaders, gain actionable insights, and enhance your expertise in this rapidly evolving field of oncology care.
Friday May 23rd 2025
8AM - 5PM
Hotel Omni Mont-Royal
1050 Sherbrooke St W, Montreal, Quebec H3A 2R6
Virtually
on Zoom
For any questions, please contact Christina Raneburger, Associate Director of St. Mary’s Research Centre.
CONFERENCE AGENDA
Morning Session | Moderator: Dr. Marie Husdon
Diagnosis, management and advances in organ specific
immune-related adverse events (irAEs):
9:30
Break
12:00
Lunch
Afternoon Session | Moderator: Dr. Jamil Asselah
13:00
Pulmonary toxicities of novel anti-cancer drugs
Gerald Bronfman Department of Oncology, McGill University
13:45
Toxicities associated with engineered cell therapies and bispecific antibodies
Ludwig-Maximilians-
14:45
Break
15:00
Novel tyrosine kinase combinations and their associated toxicities
Department of Medicine, McGill University
15:45
The next frontier of toxicity anti-cancer research
Department of Medicine, Université de Montréal
Department of Medicine, Université de Montréal
16:45
QUESTIONS & CLOSING REMARKS
*These speakers will be presenting virtually
Morning Session-Moderator: Dr. Marie Hudson
SPEAKERS
Dr. Khashayar Esfahani
Assistant Professor, Department of Oncology, McGill University
Topic: Welcome Address
Oliver Terry
M.D. Candidate 2027, Department of Medicine, McGill University
Topic: Patient Perspective
Dr. Christopher Ma
Gastroenterologist and Associate Professor, Cumming School of Medicine, University of Calgary
Topic: Gastrointestinal irAEs
Dr. Nicole Leboeuf
Vice Chair, Department of Dermatology, Dana-Farber Brigham Cancer Center
Topic: Skin irAEs
Dr. Shahin Jamal
Clinical Associate Professor, Division of Rheumatology, University of British Columbia
Topic: Rheumatological irAes
Dr. Javid Moslehi
Chief Cardiologist and Professor, Cardio-Oncology and Immunology, University of California San Francisco Health
Topic: cardiac irAEs
Dr. Carmela Pepe
Assistant Professor, Gerald Bronfman Department of Oncology, McGill University
Topic: Pulmonary toxicities of novel anti-cancer drugs
Dr. Kai Rejeski
Clinician Scientist, Ludwig-Maximilians-
Dr. Wilson H. Miller
Professor, Department of Medicine, McGill University
Topic: Novel tyrosine kinase combinations and their associated toxicities
Dr. Bertrand Routy
Associate Professor, Department of Medicine, Université de Montréal
Topic: The next frontier of toxicity anti-cancer research
Dr. Arielle Elkrief
Assistant Clinical Professor, Department of Medicine, Université de Montréal
Topic: The next frontier of toxicity anti-cancer research
MODERATORS
Dr. Marie Hudson
Associate Professor, Division of Clinical and Translational Research, McGill University
Dr. Jamil Asselah
Associate Professor, Gerald Bronfman Department of Oncology, McGill University
SPONSORS
We enable and support St. Mary’s Hospital Centre’s goals and objectives for the Next Century of Care by raising funds and awareness to better community healthcare: research, teaching, clinical care, and critical infrastructure.
The Edward W. Tinmouth Lectureship in Community Cancer Care
PHARMACEUTICAL SPONSORS
Platinum:
Gold:
Silver:
Bronze:
